Cytochrome P450 and Subjective Cannabis Response in Youth Cannabis Use Disorder

Date Added
March 2nd, 2021
PRO Number
Pro00107842
Researcher
Rachel Tomko

List of Studies


Keywords
Adolescents, Genetics, Psychiatry, Substance Use
Summary

Eligible adolescents and emerging adults (ages 12-25) who have used cannabis in the past year will attend 1-2 laboratory visits. They will complete a series of interviews and self-report measures, including assessment of cannabis quantity and frequency, subjective effects of cannabis, and problems due to cannabis use. They will provide a urine sample for analysis of a THC metabolite and they will provide a blood sample for analysis of genes related to cytochrome P450 enzyme activity, which are thought to be associated with metabolism of THC.

Institution
MUSC
Recruitment Contact
Youth Collaborative
843-792-9257
youth@musc.edu

Brief Computerized Intervention for Reducing Adolescent Cannabis and Alcohol Use

Date Added
March 2nd, 2021
PRO Number
Pro00106723
Researcher
Austin Hahn

List of Studies

Keywords
Adolescents, Alcohol, Substance Use
Summary

The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and/or cannabis use. Youth will be recruited from the Center for Drug and Alcohol Programs (CDAP) Clinic in the Department of Psychiatry at MUSC. Follow-up assessments will be conducted at one- and three-months following treatment.

Institution
MUSC
Recruitment Contact
Austin Hahn
843-792-5200
hahna@musc.edu

Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People

Date Added
February 22nd, 2021
PRO Number
Pro00105369
Researcher
Carla Danielson

List of Studies


Keywords
Adolescents, HIV / AIDS, Substance Use
Summary

Human subjects are being recruited for the proposed study to participate in usability testing for a virtual reality technology tool to be refined for assessment and prevention of risky sexual and substance use behaviors. Specifically, 15 adolescents, 15 young men, and 15 front line health care providers will participate in qualitative interviews and focus groups. Targeted enrollment is based on estimates from the existing clinical population treated by the local clinics from which participants will be recruited and the candidate's experience conducting clinical studies at these sites.

Institution
MUSC
Recruitment Contact
Nathalie Slick
843) 408-6140
slick@musc.edu

Sex Differences in the Effects of Early Childhood Adversity on Laboratory-Induced Stress and Craving among Individuals with Opioid Use Disorder

Date Added
February 2nd, 2021
PRO Number
Pro00104087
Researcher
Delisa Brown

List of Studies


Keywords
Drug Studies, Pain, Psychiatry, Stress Disorders, Substance Use
Summary

This study will examine the effects of early childhood adversity on stress and craving among individuals with opioid use disorder. Study participants will complete a total of three visits, including a 1-month follow-up visit. Participants will be asked to complete questionnaires about thier mood, anxiety, drug use, craving and adverse childhood events. They will listen to personalized scripts about a stressful situation, a time when they used opioid and a relaxing situation and their heart rate, skin conductance and cortisol are measured.

Institution
MUSC
Recruitment Contact
Delisa Brown
843-792-2388
browdg@musc.edu

Endocannabinoid Dysregulation in Cannabis Dependence and Acute Cannabis Withdrawal

Date Added
December 1st, 2020
PRO Number
Pro00105095
Researcher
Erin Martin

List of Studies

Keywords
Substance Use
Summary

The purpose of this study is to determine if certain chemicals in the body, called endocannabinoids, are affected by heavy marijuana use or marijuana withdrawal. Participation lasts approximately five weeks. In the first week, participants can use marijuana as usual and will complete mobile assessments asking about their current feelings four times each day for seven days. Participants will also complete three 5-hour laboratory visits during this week to assess levels of endocannabinoids in the blood at different times of day. One month after the first laboratory visit, participants will complete the same tasks (three laboratory visits and daily mobile assessments) while maintaining abstinence from marijuana for one week.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

Effects of a Novel mGluR5 Negative Allosteric Modulator on Alcohol Drinking, Neurochemistry, and Brain Reactivity to Alcohol Cues in Alcohol Use Disorder

Date Added
October 6th, 2020
PRO Number
Pro00102334
Researcher
James Prisciandaro

List of Studies


Keywords
Alcohol, Brain, Drug Studies, Substance Use
Summary

This Phase II clinical research study evaluates both the safety and effectiveness of an FDA-regulated medication presently in the initial stages of development for alcohol use disorder treatment (GET73), and will test whether GET73 alters brain chemicals and function, response to alcohol ingestion, and the desire for alcohol. Participants will be randomly assigned to one of two medication treatment groups (GET73 or placebo). Study medication will be taken for 8 days, with approximately 4 study visits, and a "bar-lab" procedure and 2 MRI brain imaging scans will be completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

Institution
MUSC
Recruitment Contact
Katy Fuqua
(843) 792-1452
fuquama@musc.edu

Opioids, overdose, and medication-assisted treatment (MAT)

Date Added
September 3rd, 2020
PRO Number
Pro00101654
Researcher
Tanya Saraiya

List of Studies

Keywords
Substance Use
Summary

This study proposes to collect pilot data that will inform a future grant application. We propose to complete interviews (60 min) on 25 individuals who are currently or have previously used opioids and are either currently on MAT or chose to not begin MAT. Semi-structured interviews will identify (1) what individual and treatment factors helped participants initiate MAT or, conversely, inhibited engagement in MAT, (2) what concerns they had about starting MAT, and (3) encouraging them to reflect on what additional information could have helped them initiate MAT sooner. Eligible participants will be compensated $20 for their participation in the study.

Institution
MUSC
Recruitment Contact
Tanya Saraiya
843-792-9383
saraiya@musc.edu

MPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience

Date Added
September 1st, 2020
PRO Number
Pro00102709
Researcher
Lisa McTeague

List of Studies


Keywords
Alcohol, Brain, Drug Studies, Psychiatry, Substance Use
Summary

The purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techniques that use magnetic pulses to temporarily excite specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). TBS, which is a form of TMS, will be applied over the medial prefrontal cortex, (MPFC), which has been shown to be involved with drinking patterns and alcohol consumption. This study will test whether TBS can be used as an alternative tool to reduce the desire to use alcohol and reducing the brain's response to alcohol-related pictures.

Institution
MUSC
Recruitment Contact
Charleston Alcohol Research Center
(843) 792-1222
alcoholstudy@musc.edu

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of EMB-001 in Subjects with Moderate-to-Severe Cocaine Use Disorder

Date Added
June 25th, 2020
PRO Number
Pro00101206
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This study is looking at an investigational medication called EMB-001, which is a combination of metyrapone and oxazepam, to see if it may be an effective treatment for cocaine use disorder. Participants will undergo screening procedures to determine eligibility, and eligible participants will take either EMB-001 or placebo twice a day for 13 weeks. During this time, participants will come to the office two times a week to meet with study personnel, and they will attend a one-month follow-up visit.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkini@musc.edu

Establishing the Neurostructural and Clinical Impact of Brain Iron Dysregulation in Cocaine Use Disorder

Date Added
April 21st, 2020
PRO Number
Pro00093920
Researcher
Jens Jensen

List of Studies


Keywords
Brain, Substance Use
Summary

The purpose of this research study is to understand if high brain iron in individuals who use cocaine is related to the severity of cocaine use disorder. We will use non-invasive brain MRI to examine if high brain iron is associated with 1) abnormal brain circuits, and 2) behavioral and cognitive problems. The consists of a screening visit to determine eligibility and an MRI scanning visit.

Institution
MUSC
Recruitment Contact
Zoe Brasher
843-730-3263
brasherz@musc.edu



-- OR --